The biotech firm reported higher operating costs and lower cash reserves for the year ended March 31, 2026.
Medicenna Therapeutics Corp. reported a GAAP loss per share of C$0.22 for the fiscal year ended March 31, 2026. The company ended the period with C$6.3 million in cash and cash equivalents, down from prior levels.
Operating costs rose to C$22.4 million from C$20.4 million in the previous fiscal year. The increase reflects ongoing research and development expenditures amid clinical-stage programs.
No immediate market reaction was disclosed in the release.